Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $160.00 short call and a strike $165.00 long call offers a potential 8.93% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $160.00 by expiration. The full premium credit of $0.41 would be kept by the premium seller. The risk of $4.59 would be incurred if the stock rose above the $165.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 29.89 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
Thu, 08 Aug 2019 13:00:15 +0000
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down
Thu, 08 Aug 2019 12:34:12 +0000
Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
Wed, 07 Aug 2019 13:32:01 +0000
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie
Tue, 06 Aug 2019 19:00:00 +0000
The drugmaker's Q2 revenue and earnings beats enable it to raise full-year guidance.
Allergan beats second-quarter expectations, boosts full-year guidance
Tue, 06 Aug 2019 17:19:00 +0000
Growth in sales of anti-wrinkle treatment Botox and dermal filler Juvaderm helped drive Allergan Plc to an earnings beat on Tuesday, but gains were offset by a decline in Restasis and CoolSculpting sales.
Also on Market Tamer…
Follow Us on Facebook